She has over 15 years of experience in management positions in the biopharmaceutical/biotechnology industry, including global management of drug development lifecycle, from pre-clinical to on-market stage, and extensive experience in drug/diagnostic co-development and personalized healthcare in oncology. As Life Cycle Leader, Zelboraf (vemurafenib) for Roche Genentech, she delivered the first FDA approval in circa 5 years from first time in man, a record on its own, doubled by the first ever concurrent US approval of a drug and its companion diagnostic (a cobas 4800 BRAF Mutation Test).